|
EPO906 Therapy in Patients with Advanced Colorectal Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about EPO906 Therapy in Patients with Advanced Colorectal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. EPO906 Therapy in Patients with Advanced Colorectal Cancer Clinical research trials and EPO906 Therapy in Patients with Advanced Colorectal Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as EPO906 Therapy in Patients with Advanced Colorectal Cancer. EPO906 Therapy in Patients with Advanced Colorectal Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a EPO906 Therapy in Patients with Advanced Colorectal Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their EPO906 Therapy in Patients with Advanced Colorectal Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > EPO906 Therapy in Patients with Advanced Colorectal Cancer  EPO906 Therapy in Patients with Advanced Colorectal Cancer
EPO906 Therapy in Patients with Advanced Colorectal Cancer
For Condition: Colonic Neoplasms,Colorectal Neoplasms
Status: Suspended
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must meet the following criteria to be eligible for the study: - Histologically or cytologically documented evidence of colorectal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) - The patient should have failed or progressed on no more than two prior chemotherapies for metastatic disease (the prior chemotherapy must have included a fluoropyrimidine and either Irinotecan or oxaliplatin, or any combination of these agents, with the last chemotherapy having contained Irinotecan or oxaliplatin) - Patients who have received only adjuvant therapy for their disease are eligible, as long as they have relapsed within six months of completing such therapy and that therapy contained 5-FU and Irinotecan or oxaliplatin administered in combination as part of an investigational protocol - Must have a life expectancy of greater than three (3) months. Exclusion Criteria The following patients are not eligible for the study: - Patients with symptomatic CNS metastases or leptomeningeal involvement - Patients with unresolved bowel obstruction - Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 - Patients with severe cardiac insufficiency - Patients who have undergone major surgery for any cause less than 4 weeks prior to study entry - Patients with radiation therapy or chemotherapy within the last four weeks - Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports - History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ - Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae - HIV+ patients - Pregnant or lactating females
Total Enrollment: 48
Location and Contact Information:
San Juan CCOP VA Medical Center
San Juan, , 00927
Puerto Rico
UCLA Medical Center
Los Angeles, California, 90095
United States
Cancer Institute of New Jersey (CINJ)
New Brunswick, New Jersey, 08901
United States
University of Pennsylvania Presbyterian Medical Center
Philadelphia, Pennsylvania, 19104-4238
United States
Additional Information:
Study ID Numbers: CEPO906A-2201;
Study Start Date: May 2002
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035087
Other Colorectal Neoplasms Studies:
1. Women's Health Initiative (WHI)
2. EPO906 Therapy in Patients with Advanced Colorectal Cancer
3. A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
4. An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer
5. First-line treatment of metastatic colorectal cancer with oxaliplatin/5-FU/leucovorin plus PTK787/ZK 222584 or placebo
Related Studies:
Other Colorectal Neoplasms Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
EPO906 Therapy in Patients with Advanced Colorectal Cancer
|
|
|
|
|
|
|
|
